F8 and Hepatitis: However, AAV clinical trials targeting liver will likely exclude haemophilia patients with pre-existing liver damage due to the acquisition of hepatitis or HIV from contaminated blood products from factor replacement therapy, or those individuals who have developed inhibitory antibodies to plasma FVIII or pre-existing immune responses to the AAV capsid.